BACKGROUND: Intravenously administered tissue plasminogen activator (IV tPA) remains the only approved therapeutic agent for arterial recanalization in acute ischemic stroke (AIS). Considerable proportion of AIS patients demonstrate changes in their neurologic status within the first 24 hours of intravenous thrombolysis with IV tPA. However, there are little available data on the course of clinical recovery in subacute 2- to 24-hour window and its impact. We evaluated whether neurologic improvement at 2 and 24 hours after IV tPA bolus can predict functional outcomes in AIS patients at 3 months. METHODS: Data for consecutive AIS patients treated with IV tPA within 4.5 hours of symptom onset during 2007-2011 were prospectively entered in our ...
Large-scale observational studies of acute ischemic stroke (AIS) promise to reveal mechanisms underl...
Background: To determine whether it is possible to predict intravenous thrombolytic therapy (IVT) ou...
The objective of our study is to detect the patient group that will most benefit from intravenous (I...
BACKGROUND: Intravenously administered tissue plasminogen activator (IV tPA) remains the only approv...
Background : Patients with acute ischemic stroke who had early neurological improvement had better f...
International audienceOBJECTIVE: To evaluate whether very early neurologic improvement (VENI) after ...
Background : Despite the increasing use of recombinant tissue plasminogen activator (rt-PA) in acute...
BACKGROUND: Recanalization of occluded intracranial arteries remains the aim of intravenous (IV) tis...
Objective : The aim of this study was to determine the factors associated with early neurological im...
Introduction: Evidence of the intravenous tissue plasminogen activator (tPA) efficacy beyond the 4.5...
Although onset-to-treatment time is associated with early clinical recovery in acute ischemic stroke...
Although onset-to-treatment time is associated with early clinical recovery in acute ischemic stroke...
Background and Purpose—Ongoing clinical trials are using early response to intravenous tissue-type p...
BACKGROUND: Recanalization precedes clinical improvement in patients treated with IV TPA. Transcrani...
BACKGROUND AND PURPOSE: Large-scale observational studies of acute ischemic stroke (AIS) promise to ...
Large-scale observational studies of acute ischemic stroke (AIS) promise to reveal mechanisms underl...
Background: To determine whether it is possible to predict intravenous thrombolytic therapy (IVT) ou...
The objective of our study is to detect the patient group that will most benefit from intravenous (I...
BACKGROUND: Intravenously administered tissue plasminogen activator (IV tPA) remains the only approv...
Background : Patients with acute ischemic stroke who had early neurological improvement had better f...
International audienceOBJECTIVE: To evaluate whether very early neurologic improvement (VENI) after ...
Background : Despite the increasing use of recombinant tissue plasminogen activator (rt-PA) in acute...
BACKGROUND: Recanalization of occluded intracranial arteries remains the aim of intravenous (IV) tis...
Objective : The aim of this study was to determine the factors associated with early neurological im...
Introduction: Evidence of the intravenous tissue plasminogen activator (tPA) efficacy beyond the 4.5...
Although onset-to-treatment time is associated with early clinical recovery in acute ischemic stroke...
Although onset-to-treatment time is associated with early clinical recovery in acute ischemic stroke...
Background and Purpose—Ongoing clinical trials are using early response to intravenous tissue-type p...
BACKGROUND: Recanalization precedes clinical improvement in patients treated with IV TPA. Transcrani...
BACKGROUND AND PURPOSE: Large-scale observational studies of acute ischemic stroke (AIS) promise to ...
Large-scale observational studies of acute ischemic stroke (AIS) promise to reveal mechanisms underl...
Background: To determine whether it is possible to predict intravenous thrombolytic therapy (IVT) ou...
The objective of our study is to detect the patient group that will most benefit from intravenous (I...